La cessation de la chimiothérapie pour le traitement de l'adénocarcinome pancréatique avancé : recherche de facteurs prédictifs de mort imminente by Frigeri, M.
UNIVERSITE DE LAUSANNE - FACULTE DE BIOLOGIE ET DE MEDECINE 
Département d'oncologie 
et 
Service d'oncologie médicale 
La cessation de la chimiothérapie pour le traitement de 
l'adénocarcinome pancréatique avancé: recherche de facteurs 
prédictifs de mort imminente. 
THESE 
préparée sous la direction du Professeur Olivier Michielin 
(avec la collaboration du Docteur Piercarlo Saletti) 
et présentée à la Faculté de biologie et de médecine de 
l'Université de Lausanne pour l'obtention du grade de 
DOCTEUR EN MEDECINE 
par 
':l>'n Mauro FRIGERI h 7 F )-, \) :::i 
Médecin diplômé de la Confédération Suisse 
Originaire de Lam one (Ti ci no) 
Lausanne 
2013 
Bibliothèque Unive~sitaire 
de Médecine/ B1UM 
CHUV-BH08 - Bugnon 46 
CH-îüî î Lausanne 
UNIL 1 Université de Lausanne 
Ecole Doctorale 
Doctorat en médecine 
Imprimatur 
Vu le rapport présenté par le jury d'examen, composé de 
Directeur de thèse 
Co-Directeur de thèse 
Expert 
Monsieur le Professeur 0 livier Michielin 
Directrice de l'Ecole Madame le Professeur Stephanie Clarlœ 
doctorale 
la Commission MD de l'Ecole doctorale autorise l'impression de la thèse de 
Monsieur Mauro Frigeri 
intitulée 
La cessation de la chimiothérapie pour le traitement de 
l'adénocarcinome pancréatique avancé: recherche de facteurs 
prédictifs de mort imminente 
Lausanne, le 14 juin 2013 
pour Le Doyen 
de la Faculté de Biologie et de Médecine 
Madante le Professeur Stephanie Clarke 
Directrice de l'Ecole doctorale 
La cessation de la chimiothérapie pour le traitement de l'adénocarcinome 
pancréatique avancé: recherche de facteurs prédictifs de mort imminente. 
Publié le 1er juin 2012: Chemotherapy in patients with advanced pancreatic cancer: tao close to death? 
DOi 10.1007/s00520-012-1505-9 
Dans cette étude rétrospective, nous reportons des données relatives à la 
chimiothérapie chez des patients atteints d'adénocarcinome pancréatique avancé, avec 
attention à la durée du temps qui passe entre le dernier traitement et la mort. En outre, 
nous analysons des paramètres cliniques et de laboratoire, enregistrés à la dernière 
chimiothérapie, avec le but d'identifier des facteurs de risque pour un décès proche. 
L'analyse rétrospective est effectuée sur des patients avec adénocarcinome 
pancréatique avancé, qui ont bénéficié au moins d'une ligne de chimiothérapie. Nous 
avons enregistré les données concernant la chimiothérapie (régimes, lignes et date de 
la dernière administration) et avons choisi et enregistré des facteurs cliniques et de 
laboratoire, qui étaient récoltés à la dernière chimiothérapie (performance status, 
présence d'ascite, hémoglobine, leucocytes, plaquettes, bilirubine totale, albumine, 
LDH, protéine C-réactive et Ca19-9). Des analyses statistiques (univariée et 
multivariée) sont effectuées pour étudier la relation entre ces facteurs et le temps de 
survie, à la recherche de facteurs prédictifs de mort imminente. 
Nous avons analysé les données de 231 patients: hommes/femmes, 53/47%; 
métastatique/localement avancé, 80/20%; âge médian 66 ans (gamme 32-85). Tous 
les patients sont décédés à cause de la progression de la maladie. La survie globale 
médiane est 6.1 mois (95% Cl 5.1-7.2). Lors de la dernière chimiothérapie, le 
performance status est 0-1 pour 37% et 2 pour 63% des patients. Cinquante-neuf pour 
cent des patients reçoivent une ligne de chimiothérapie, 32, 8 et 1 % reçoivent des 
chimiothérapies de deuxième, troisième, quatrième ligne, respectivement. L'intervalle 
entre la dernière administration de chimiothérapie et le décès est <4 semaines pour 
24%, 4-12 semaines pour 47% et >12 semaines pour 29% des patients. La survie 
médiane à partir de la dernière chimiothérapie jusqu'au décès est 7.5 semaines (95% 
Cl 6.7-8.4). L'ascite, la leucocytose, des valeurs élevées de bilirubine, LDH, protéine C-
réactive et Ca19-9, et des valeurs abaissées d'albumine sont associés à une survie 
plus courte à l'analyse univariée; néanmoins, aucun de ces facteurs n'est corrélé à la 
survie de façon significative à l'analyse multivariée. 
Nous en concluons qu'une proportion significative de patients avec adénocarcinome 
pancréatique avancé reçoit la chimiothérapie dans le dernier mois de vie, et que les 
paramètres cliniques et de laboratoire enregistrés à la dernière chimiothérapie ne 
prédisent pas une survie plus courte. 
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Abstract 
Pwpose We evaluated the attitude in using chemotherapy 
near the end of life in advanced pancreatic adenocarcinoma 
(PAC). Clinical and laboratmy parameters recorded at last 
chemotherapy administration were analyzed, in order to 
identify risk factors for imminent death. 
Methods Retrospective analysis of patients who undetwent 
at least one line of palliative chemotherapy was made. Data 
conceming chemotherapy (regimens, lines, and date of last 
administration) were collected. Clinical and laboratory fac-
tors recorded at last chemotherapy administration were: 
performance status, presence of ascites, hemoglobin, white 
blood cell (WBC), platelets, total bilirnbin, albumin, LDH, 
C-reactive protein (C-rp), and Ca 19.9. 
Results We analyzed 231 patients: males/females, 53/47 %; 
metastatic/locally advanced disease, 80/20 %; and median 
age, 66 years (range 32-85). All patients died due to disease 
progression. Median overall survival was 6.1 months (95 % 
CI 5.1-7 .2). At the last chemotherapy delivery, pe1fonnance 
status was 0-1in37 % and 2 in 63 %. Fifty-nine percent of 
patients received one chemotherapy line, while 32, 8, and 
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1 % had second-, third-, and fourth line, respectively. The 
interval between last chemotherapy administration and 
death was <4 weeks in 24 %, <:4-12 in 47 %, and >12 in 
29 %. Median survival from last chemotherapy to death was 
7.5 weeks (95 % CI 6.7-8.4). In a univariate analysis, 
ascites, elevated WBC, bilirnbin, LDH, C-rp and Ca 19.9, 
and reduced albumin were found to predict shorter survival; 
however, none of them remained significant in a multivari-
ate analysis. 
Conclusions A significant proportion of patients with ad-
vanced PAC received chemotherapy within the last month of 
life. The clinical and laboratory parameters recorded at last 
chemotherapy delivery did not predict shorter survival. 
Keywords Pancreatic cancer ·Palliative chemotherapy ·End 
oflife · Aggressiveness 
Introduction 
Pancreatic adenocarcinoma (PAC) is one the most lethal 
malignancies and the fourth leading cause of cancer-
related death in USA in 2010 [1]. Prognosis for patients 
with locally advanced or metastatic disease is poor. In 
advanced PAC, chemotherapy increases survival compared 
to best supportive care (BSC). However, the lack of stan-
dardized protocols of BSC represents a methodologic limi-
tation in interpreting this finding [2, 3]. In 1997, 
gemcitabine was found to improve both median overall 
survival (OS, 5.65 vs 4.41 months, p00.0025) and clinical 
benefit response (23.8 vs 4.8 %, p 0 0.0022) compared to 5-
fluorouracil [4]. Gemcitabine-based regimens failed to dem-
onstrate a significant or clinically relevant improvement in 
OS over gemcitabine alone. Recently, the FOLFIRINOX 
regimen significantly improved 0 S over single-agent 
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gemcitabine (11. 1 vs 6.8 months, p<0.001) in patients with 
metastatic disease, good performance status (PS), and nor-
mal bilirubin [5]. CmTently, there is no accepted standard for 
gemcitabine refractory patients. An OS advantage has been 
reported using an oxaliplatin-based regimen compared to 
BSC [6]. 
To date, the use of palliative chemotherapy is increasing 
due to the availability of more drugs and a wider range of 
indications [7]. Many oncologists consider chemotherapy 
near the end of life (EoL) as aggressive and typically un-
necessary. On the other hand, patients have to face the 
difficult decision of chemotherapy near the EoL: such treat-
ment may prolong survival and/or reduce their symptoms; 
however, it may cause adverse effects, such as increasing 
toxicity, preventing patients from preparing to die, acceler-
ating hospitalization and emergency department visits, pre-
cluding entry into palliative care services, and increasing 
costs. The time when it is more appropriate to discontinue 
chemotherapy is often a difficult decision, given that 
patients', family members', and physicians' attitude is sub-
stantially different. Prescription of new anticancer therapies 
or the prolonging of the ongoing treatments near the EoL 
emerged as one of the most relevant factors poorly influ-
encing the quality of care [8]. In unresectable PAC, some 
prognostic factors such as Ca 19.9 value, stage of disease, 
and h·eatment modality are identified as independent factor 
to worsen OS [9]. In addition, PS, peritoneal carcinomato-
sis, and C-reactive protein (C-rp) were identified as prog-
nostic factors in gemcitabine refractmy patients [10]. 
Most of data relating to the use of chemotherapy at the 
EoL arise from trials involving patients with various cancer 
types. Here, we aimed to describe the patterns of the use of 
chemotherapy in a cohmi of patients with advanced PAC 
who <lied due to disease progression. In particular, the 
study's objective was to detennine the proportion of patients 
receiving chemotherapy according to the tüne between the 
last chemotherapy administration and death, and treatment 
line. Moreover, in order to identify smvival predictors in 
this specific setting, we analyzed clinical and biochemical 
variables recorded at the last delivery of chemotherapy and 
their independent value as prognostic factors for survival. 
Patients and methods 
Study population 
Inclusion criteria in this retrospective study conducted at the 
Oncology lnstitute of Southern Switzerland were: (1) biopsy 
diagnosed as locally advanced or metastatic PAC and treated 
was analyzed for this study; (2) patients unde1went at least 
one line of palliative chemotherapy; and (3) patients <lied 
due to progressive disease. Approval for the study was 
%) Springer 
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obtained from the institutional review board of the Oncolo-
gy Institute of Southern Switzerland. Ali patients provided 
an infonned consent. 
Data collection 
The Oncology Institute of Southern Switzerland database 
provided ail patients' clinical charts and ail the following 
data: (1) patients characteristics at diagnosis: age, gender, 
Eastern Cooperative Oncology Group (ECOG) PS, stage of 
disease, prima1y tumor location, number of metastatic sites, 
Ca 19.9, and weight Joss; (2) treatment characteristics: 
number of chemotherapy lines, chemotherapy regimens, 
and time of last administration of chemotherapy before 
death (divided in three periods: <4 weeks, 4 to 12 weeks, 
and > 12 weeks), according to the chemotherapy line; and 
(3) clinical and laborat01y parameters recorded at the last 
administration of chemotherapy: ECOG PS, presence of 
ascites, white blood cell (WBC), hemoglobin (Hb ), platelets 
(PLT), total bilirubin, albumin, LDH, C-rp, and Ca 19.9. 
These variables were selected because they have been found 
to be of prognostic significance in patients with terminal 
cancer [11]. The relationship between chemotherapy pat-
terns and clinical and laboratmy parameters, recorded at 
the last chemotherapy delive1y, and survival titne were 
examined using uni- and multivariate analyses. 
Statistical analysis 
For descriptive purposes, continuous variables were sum-
marized as medians, and categorical variables as proportions 
with 95 % CI. Inferential comparisons were carried out by t 
or Mann-Whitney U test according to data determined by 
the Kolmogorov-Smirnov test. Fisher exact test was utilized 
to assess significance among categorical variables. Statisti-
cal significance was determined as p<0.05 with a two-sided 
test. OS was calculated from diagnosis to death. Survival 
from last chemotherapy delive1y to death was calculated. 
Both survival variables were analyzed with the Kaplan-
Meier method, while comparisons among subgroups were 
performed with log rank test. For smvival analysis purposes, 
ail variables were dichotomized. Statistically significant and 
borderline significant variables (p<O. l) were included in the 
Cox regression analysis. Ali statistical analyses were per-
fmmed using SPSS software package version 15 (SPSS Inc, 
Chicago, IL). 
Results 
From 1993 to 2010, 231 patients with advanced PAC were 
identified (Table 1 ). The median age was of 66 years and 
53 % were males. Tumor was localized to the head in 55 % 
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Table 1 Patients characteristics 
at diagnosis N(%) Median OS p value 95 % Cl 
Patients 231 (1 OO) 
Median age (range) 66 years (32-85) 
Sex 
Males 
Fe males 
PS (ECOG) 
0 
1-2 
Setting 
Metastatic 
Local \y advanced 
Tumor location 
Head 
Body-ta il 
Liver metastases 
Yes 
No 
Sites of metastases 
1 
<::2 
Weight Joss 
Yes 
OS overall survival (in months), No 
PS perfonnance status (ECOG) 
of patients, and most of the patients presented with meta-
static disease. The median value of CAl 9 .9 was 532 (range 
0-972,000), while the median OS was 6.1 months (95 % CI 
5.1-7.2). 
The status of chemotherapy lines before death is summa-
rized in Table 2. In details, first line was the only treatment 
in approximately 60 % of patients (single-agent gemcitabine 
in 70 %, gemcitabine-based combinations or fluoropyrimi-
dine in 30 %). About one third of patients received second 
line (either fluoropyrimidine- or gemcitabine-based regi-
mens ), while 9 % were treated with third- and fourth line 
(either single agents or within phase I trials). 
The median survival from last chemotherapy administration 
to death was 7.5 weeks (range 0.43-75.5; 95 % CI 6.7-8.4). 
Approximately 24 % of patients received last chemotherapy 
within 4 weeks before death (Table 3); among them, the last 
dose of chemotherapy was given within 2 weeks before death 
Table 2 Last line 
of chemotherapy 
before death 
Chemotherapy line No. of patients(%) 
First 137 (59.3) 
Second 74 (32) 
Third 18 (7.8) 
Fourth 2 (0.9) 
123 (53) 6.14 4.74-7.54 
108 (47) 6.27 0.30 4.60-7.94 
68 (30) 9.3 5.61-12.98 
163 (70) 4.9 <0.001 3.79-6.12 
185 (80) 5.7 4.71-10.39 
46 (20) 7.5 0.24 4.54-6.95 
126 (55) 6.7 5.62-7.84 
105 (45) 4.9 0.84 3.49-6.43 
147 (67) 4.8 3.56-6.22 
84 (37) 7.7 0.009 5.77-9.66 
191 (83) 6.7 5.61-7.85 
40 (17) 3.7 0.068 1.72-5.69 
107 (46) 5.38 4.27-6.49 
124 (54) 6.73 0.47 5.55-7.91 
in 7 %. With respect to chemotherapy during the last month of 
life, two periods oftime (from 1993 to 2003 and from 2004 to 
2010) were obsetved separately: 32 out of108 (30 %) patients 
were treated in the first period, compared to 27 out of 123 
(22 % ) patients in the second one. Thirty-six out of 55 ( 65 % ) 
patients who <lied within 4 weeks before the last chemotheraw 
adminish·ation were in first line. 
Obseiving the last chemotherapy delivery, ECOG PS was 
0-1 in 38 % and 2 in 62 %, respectively. Ascites was present 
in 41 % of cases. Furthermore, median values for laboratory 
parameters were: WBC 7.9x 109/L, Hb 10.5 g/dl, PLT 212x 
109/L, total bilirubin 12.7 µmol/L, albumin 33 g/L, LDH 
440 U/L, C-rp 37 mg/L, and Ca 19.9 2, 125 U/mL. At 
univariate analysis, presence of ascites, elevated WBC, bil-
irubin, LDH, C-rp, and Ca 19.9 and reduced albumin were 
found to predict sh01ier survival. However, none of them 
emerged as independent predictors of survival at multivari-
ate analysis (Table 4). 
Table 3 Number of 
patients treated accord-
ing to the time between 
the last administration 
of chemotherapy and 
death 
Time (weeks) 
<4 
4-12 
>12 
No. of patients (%) 
55 (23.8) 
109 (47.2) 
67 (29) 
~ Springer 
Table 4 Characteristics at last 
administration of chemotherapy: N(o/o) 
uni- and multivariate analysis 
Age 
<66 years 112 (48) 
266 years 119 (52) 
PS (ECOG) 
0-1 85 (37) 
2 139 (63) 
Ascites (n 0 226) 
Yes 92 (41) 
No 134 (59) 
WBC (n0219) 
<11X109/L 161 (73) 
211 x109/L 58 (27) 
Hb (n0217) 
<10 g/dl 34 (16) 
210 g/dl 183 (84) 
PLT (n0219) 
<400X109/L 190 (87) 
2400x 109/L 29 (13) 
Bilirubin (n0207) 
<34 mol/L 189 (91) 
234 mol/L 18 (9) 
Albumin (110145) 
<35 g/L 88 (61) 
235 g/L 57 (49) 
LDH (n0183) 
<500 U/L 121 (66) 
2500 U/L 62 (34) 
c-rp (n0148) 
<5 mg/L 16 (11) 
25 mg/L 132 (89) 
OS overall survival (in weeks), 
Ca 19.9 (110121) PS performance status (ECOG), 
WBC white blood cell, Hb he- <1,000 U/ml 44 (36) 
moglobin, PLTplatelets, C-rp C-
reactive protein 
21,000 U/ml 77 (64) 
Discussion 
The role of chemotherapy near the EoL is a complex issue. 
Its administration at life's end involves a proper oncological 
assessment, a focused attention toward the patient's goals of 
care, and a balancing of perspectives of the patient and 
treating oncologist. While there is no accepted medical 
definition of futile care, chemotherapy may be overused in 
tem1inally i1l cancer patients, despite its little chance of 
benefit. Most of available data on this matter are offered 
by retrospective population or institution-based death-
centered studies [12-19]. Within this body of evidence, the 
concept of futility could particularly apply in advanced 
~ Springer 
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Median OS U nivariate Mu ltivariate 
p value 95 % Cl p value HR 
7.5 6.12-9.01 
7.5 0.69 6.29-8.84 
8.2 6.27-10.29 
6.8 0.19 6.12-9.01 
6.0 4.32-7.67 
8.5 0.055 6.85-10.29 0.173 0.609 
8.2 6.80-9.76 
4.4 0.003 3.22-5.62 0.649 1.213 
8.0 5.75-10.24 
7.4 0.72 6.38-8.47 
7.5 6.60-8.53 
7.0 0.83 3.73-10.26 
7.7 6.94-8.48 
4.4 0.002 3.83-5.01 0.498 1.472 
6.7 5.27-8.15 
7.8 0.023 5.14-10.57 0.693 0.854 
7.7 5.73-9.69 
6.0 0.025 3.79--8.20 0.145 1.761 
13.5 4.05-23.09 
6.5 0.005 5.36-7.77 0.092 3.945 
8.3 3.95-12.61 
8.1 0.035 6.17-10.10 0.300 0.671 
PAC, an overly aggressive neoplasm, which rapidly tends 
to be unresponsive to chemotherapy. 
The main goal of our study was to report the patterns of 
chemotherapy use in patients who <lied for advanced PAC. 
Out of the 231 patients analyzed, a substantial proportion 
(24 % ) of them received chemotherapy in the last month of 
life. There are limited data in this specific setting. In a lesser 
extent but increasing over time (from 8.1 to 16.4 % in 1992-
1994 and 2004-2006, respectively), also others reported a 
significant use of chemotherapy in the last month [20]. In 
our study, according to the analysis of two different periods 
of time including a rather balanced number of patients, we 
can speculate that both the implementation of early 
Support Care Cancer 
symptoms control strategies and the improved communica-
tion between oncologists, palliative care givers, patients, 
and their families may account for the inverse trend in use 
of chemotherapy during the last month of life. Another 
explanation of the inverse trend is that many oncologists 
are reluctant to prescribe chemotherapy at the EoL, espe-
cially in aggressive neoplasms [21]. 
In our study, 65 % of patients who <lied within 4 weeks 
before last chemotherapy administration were in first line. In 
a way, this finding is somewhat cumbersome and underlies 
the need of more accurate tools for adequate patient selec-
tion. Moreover, 7 % of patients received chemotherapy in 
the last 2 weeks of life. Related to this, health care systems 
who do not provide overly aggressive care would be ones in 
which less than 10 % of patients receive chemotherapy in 
the last 14 days of life [22]. Conversely, in our cohort, 
almost 30 % of patients did not receive chemotherapy dur-
ing the last 3 months oflife, which could reflect the effort to 
both optimize the chemotherapy use and supportive 
resources. 
Similar to other solid neoplasms, chemotherapy prolongs 
survival also in advanced PAC [2]. Therefore, the crncial 
issue is not if but rather until when chemotherapy should be 
administered. Multiple factors may account for the increased 
use of chemotherapy near the EoL, and the mutual physi-
cian-patient relationship heavily influences the final thera-
peutic process. From the patient's perspective, keeping up 
faith and hope is an imp01iant defensive mechanism, in 
where chemotherapy "fights" against the disease. Moreover, 
if patients with advanced cancer are given truthful prognos-
tic and treatment information, even if they are bad, their 
hope to fight cancer is kept alive [23]. 
However, doctors may interfere with hopefulness by 
offering patients with a wide range of outcomes over which 
patients usually choose the most favorable one [24]. Many 
patients choose chemotherapy to have a small clinical ben-
efit, and its adverse effects become a minor concern for 
patients [25]. Physicians also play a critical role for the 
assessment of late-stage chemotherapy. Doctors' survival 
predictions are not always accurate, and overestimation of 
survival by at least 4 weeks has been reported in 27 % of 
cases [26-28]. Emotionally difficult and painful discussions 
between physicians and patients on prognosis are also a 
delicate factor in detennining the therapy. Managing the 
transition to palliative care when chemotherapy is failing is 
difficult, paiiicularly due to ban-iers in c01m1rnnication be-
tween patients and doctors. For instance, the oncologist may 
respond to patient and/or family distress by agreeing to an 
additional round of chemotherapy, which turns out to be the 
optimal solution rather than "doing nothing." Although this 
may temporarily solve the problem, it evades the real issue 
of cancer progression and displaces any EoL planning. At 
tünes, chemotherapy is temporarily suspended until the 
patient "gets stronger." This approach does allow an oncol-
ogist to avoid critical issues, including death, treatment 
failure, and Joss of hope for survival, enabling patients and 
families to realistically plan their limited titne left [29]. Yet, 
the most important detern1inant for the decision is the med-
ical oncologist [30]: those without communication skills are 
more likely to prescribe third- and fourth-line chemotherapy, 
impacting negatively on the quality oflife of the patient and 
its costs [31]. 
Objective indicators near the EoL may help to establish a 
realistic survival estimate, in order to prevent inappropriate 
therapies and to avoid unnecessary toxicity to the patient. 
Thus, we aimed to identify clinical and laboratory parame-
ters that could predict sh01ier survival and, consequently, 
indicate whether it is more appropriate for the patients to 
tenninate chemotherapy. While early-stage tumor prognosis 
is typically based on histopathological findings and tumor 
stage, prognosis for advanced malignancies necessitate ad-
ditional parameters. Review of literature indicates that the 
PS and indices of activity and functional autonomy are 
major predictors of outcome. In addition, signs and symp-
toms that often characterize the te1111inal phase ( anorexia, 
cachexia, weight loss, dysphagia, difficulty in swallowing, 
xerostomia dyspnea, and delirium or cognitive impainnent) 
have a prognostic impact. Among the laborat01y parameters, 
low pseudocholinesterase, high vitamin B 12, high bilirnbin, 
elevated C-rp, lymphocytopenia, and leukocytosis have also 
a prognostic significance [32]. Among the 11 clinical and 
laborat01y parameters analyzed in our study, a positive 
correlation of poor survival was identified in presence of 
ascites, low sernm albumin, and elevated leucocyte count, 
bilirnbin, LDH, C-rp, and Ca 19.9. However, none ofthese 
parameters were found to be independent prognostic factors 
at multivariate analysis. 
In a systematic review of 53 trials involving patients with 
uncurable cancer, some factors associated with survival 
were organized into four categories according to attributes 
of the host, the tumor, the treatment, and the interactions 
between the host, tumor, and treatment (symptoms, quality 
of life, PS, and laborat01y tests). PS, anemia, thrombocyto-
penia, hypoalbuminemia, and elevated sernm levels of both 
alkaline phosphatase and LDH were associated with sh01ier 
survival [33]. Similar data were reported by others in end-
stage disease [11]. Paiiicularly for advanced PAC, pretreat-
ment sernm CA 19-9 concentration is an independent prog-
nostic factor for survival [34]. Interestingly, in a recently 
published prospective study in terminally ill cancer patients, 
the PS, LDH, lymphocyte count, sernm albumin, and titne 
from initial diagnosis to diagnosis of tenninal disease were 
found to be independent prognostic factors of survival and 
f01111ed the basis of a nomogram [35]. 
The retrospective feature of our study represents a major 
limitation, as it relies on the accuracy of the hospital records. 
® Springer 
For instance, patients' symptoms, which are considered an-
other potential factor influencing the use of palliative che-
motherapy, were not included in the analysis as they were 
not properly collected. Another limitation ofthis study is the 
lack of infmmation on other validated indicators for care 
quality at EoL, namely the intensive care unit admission, 
emergency department visits, inpatients hospital admissions, 
and undernse of palliative care service [8, 22]. 
In conclusion, our study identified that a significant pro-
portion of patients with advanced PAC received chemother-
apy near the EoL. As data in this setting are limited, we 
believe that our experience offers the oppmtunity to reex-
amine how care is delivered at the EoL in this specific 
condition. Implications of these findings for eve1yday prac-
tice are that every patient must be individually assessed 
before each chemotherapy administration. Prognostic tools 
are needed in order to help oncologists whether the patient is 
fit enough for further chemotherapy and likely to survive 
long enough to benefit from the treatment, but realistically it 
is difficult to set up. More importantly, effo1is are underway 
to early integrate palliative seivices into a comprehensive 
cancer care plan, in order to optimize the quality and out-
come of EoL care. 
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